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1. Introduction
The last two decades have witnessed a growing interest in the discovery of new chemical
and pharmacological substances of animal origin. Pharmacological tests of toxins obtained
from animal venoms revealed its effects on central nervous system, mainly acting on ion
channels in heart, intestine, in vascular permeability, etc. Potential applications of these sub‐
stances have been proposed ranging from human disease treatment to plague control of ag‐
ricultural interest. In this scenario, the peptidomic analysis has played an increasingly
important role.
Venomous organisms are widespread throughout the animal kingdom, comprising more
than 100,000 species distributed in all major phyla. Virtually all ecosystems on Earth have
venomous or poisonous organisms. Venoms represent an adaptive trait, and an example of
convergent evolution. They are truly mortal cocktails, comprising unique mixtures of pepti‐
des and proteins naturally tailored by natural selection to operate in defense or attack sys‐
tems, for the prey or the victim. Venoms represent an enormous reservoir of bioactive
compounds able to cure diseases that do not respond to conventional therapies. Darwinian
evolution of animal venoms has accumulated in nature a wide variety of biological fluids
which resulted in a true combinatorial libraries of hundreds of thousands of molecules po‐
tentially active and pharmacologically useful.
Venom is a general term which refers to a variety of toxins used by certain animals that
inoculate its victims through a bite, a sting or other sharp body feature. Venoms of verte‐
brates and invertebrates contain a molecular diversity of proteins and peptides, and other
classes of substances, which together form an arsenal of highly effective agents, paralyz‐
ing and lethal, mainly used for predation and defense. We must distinguish venom from
poison, which is ingested or inhaled by the victim, being absorbed by its digestive system
or respiratory system. Animal venoms, in contrast, are administered directly into the lym‐
© 2013 Cunha; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
phatic  system,  where  it  acts  faster.  Only  those  organisms  possessing  injection  devices
(stingers,  fangs,  spines,  hypostomes,  spurs  or  harpoons)  which  allow  the  active  use  of
venom for predation can be correctly characterized as venomous. Many other animals se‐
crete  lethal  substances (insects,  centipedes,  frogs,  fish,  etc.),  but,  as  these substances are
used primarily for defense purposes, these animals are termed poisonous and cannot be
accurately characterized as venomous.
Venomous and poisonous invertebrates include cnidarians [1, 2] (sea anemones, jellyfish
and corals), some families of mollusks [3] (mainly Conidae) and arthropods [4] (scorpions,
pseudoscorpions, spiders, centipedes, ticks and hymenoptera insects, like bees, ants and
wasps). Arthropods inject their venom through fangs (spiders and centipedes) or stingers
(scorpions and pungent insects). The sting, in some insects, such as bees and wasps, is a
modified egg-laying device, called ovipositor. Some caterpillars have venom defense glands
associated to specialized bristles in the body known as urticating hairs, which can be lethal
to humans (such as the moth Lonomia) [5]. Bees use an acidic poison (apitoxin), which causes
pain in those bitten, to defend their hives and food stocks [6]. Wasps, on the other hand, use
its venom to only paralyze the prey [7]. In this way, the pray can be stored alive in food
chambers for the young. The ant Polyrhachis dives produces a poison that is applied topically
on the victim for pathogen sterilization [8]. There are many other venomous and poisonous
invertebrates, including jellyfish [9], bugs [10] and snails [11-13]. The sea wasp (Chironex
fleckeri), also called box jellyfish, has about 500,000 cnidocytes in each tentacle, containing
nematocysts, a harpoon-shaped mechanism that injects an extremely potent venom into the
victim, which causes severe physical and psychological symptoms known as Irukandji syn‐
drome. In many cases, this inoculation leads to death of the victim, that is why sea wasp is
popularly known as “the world’s most venomous creature” [14].
Loxoscelism is a condition produced by the bite of spiders from the genus Loxosceles, and
is the only proven cause of necrosis in humans of arachnological origin [15]. Loxosceles spi‐
ders can be found worldwide. However, their distribution is heavily concentrated at the
Western Hemisphere, particularly at the Americas, with more evidence in the tropics. In
urban areas of South America, the presence of this type of spider is so evident that loxo‐
scelism is considered a public health problem. Although Loxosceles bite is usually mild, it
may  ulcerate  or  cause  more  serious  dermonecrotic  injurie  and  even  systemic  reactions.
This injurie is  mainly due to the presence of  the enzyme sphingomyelinase D in spider
venom. Because the great number of diseases which mimic the loxoscelism symptoms, it
is frequently misdiagnosed by physicians [16]. Although there is no known fully effective
therapy for  loxoscelism,  research about  potential  antivenoms and vaccines  has  been ex‐
haustive,  presently  also using the peptidomic approach [17],  and many palliative thera‐
pies are reported in literature [15, 18].
Among vertebrates, only few reptiles (snakes and lizards) have developed the machinery
for venom production [9], although some fish [9, 19], amphibians [20] and mammals (pla‐
typus for example)  [21]  have venom glands.  The best  known venomous reptiles are the
snakes,  which  normally  inject  venom  into  their  prey  through  hollow  fangs.  The  snake
venom is produced by mandibular glands located below the eyes and is inoculated into
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the victim through tubular or channeled fangs. Snakes use their venom mainly for hunt‐
ing, although they can also use it  for defense. A snakebite can cause a variety of symp‐
toms  including  pain,  swelling,  tissue  damage,  decreased  blood  pressure,  seizures,
bleeding, respiratory paralysis, kidney failure and coma, and may, in severe cases, cause
the patient death. These symptoms will vary depending on snake specie. Snakebite is an
important medical emergency in many parts of the world, particularly in tropical and sub‐
tropical regions. According to World Health Organization (WHO), the incidence of snake‐
bite reaches 5 million per year, causing 2.5 million envenomations and 125,000 deaths [22].
About 80% of envenomation deaths worldwide are caused by snakebite, followed by scor‐
pion bite, which causes 15% [23]. Most affected are healthy people, such as children and
agricultural populations, usually in poor resources areas, away from health centers in low-
income countries in Africa, Asia and Latin America. As a result, WHO declared snakebite
as a health crisis and a neglected tropical disease.
In addition to snakes, there are other venomous reptiles, such as the beaded lizard (Heloder‐
ma horridum), the Gila monster (Heloderma suspectum) and other species of lizards [9]. The
composition of the Komodo dragon (Varanus komodoensis) venom is as complex as snake
venoms [24]. Because of recent studies of venom glands in squamata and analysis of nuclear
protein-coding genes, a new hypothetical clade, Toxicofera, is being proposed [25]. This
clade would include all poisonous Squamata: suborders Serpentes (snakes) and Iguania
(iguanas, agamid lizards, chameleons, etc.) and the infraorder Anguimorpha, represented
by the families Varanidae (monitor lizards), Anguidae (alligator lizards, glass lizards, etc.)
and Helodermatidae (Gila monster and beaded lizard).
Venoms can also be found in some fish, such as cartilaginous (rays, sharks and chimae‐
ras) and teleostean, including monognathus eel-like fishes, catfishes, rockfishes, waspfish‐
es,  scorpionfishes,  lionfishes,  goatfishes,  rabbitfishes,  spiderfishes,  surgeonfishes,
gurnards,  scats,  stargazers,  weever,  swarmfish,  etc.  [9,  19].  Another  venomous  fish,  the
doctor fish, also know as “reddish log sucker”, is used by some spas to feed the affected
and dead areas of the skin of psoriasis patients, leaving the healthy skin to grow. There
are venomous mammals, including solenodons, shrews, slow loris and the male platypus
[21]. There are few poisonous amphibian species [20]. Some salamanders can expel venom
through a rib of a sharp edge. There are even reports of venomous dinosaurs [26]. Sinorni‐
thosaurus, a genus of Dromaeosauridae dinosaur with feathers, may have had a venomous
bite. But this theory is still controversial. The coelophysoid dinosaur Dilophosaurus is com‐
monly portrayed in popular culture as being poisonous, but this superstition is not con‐
sidered likely by the scientific community.
Until recently, the work in toxinology involved prospecting highly toxic or lethal toxins in
animal venoms that could explain the symptoms observed clinically. Typically, such an ap‐
proach involved the isolation and structural characterization of the molecule which causes
an specific adverse effect observed when a person is envenomed. However, small molecules
with micro-effects that were not easily observed were neglected or poorly studied. This sit‐
uation changed in recent years with the improvement in sensitivity, resolution and accuracy
of mass spectrometry and other techniques used in proteomic toxinology. With the advent
Peptidomic Analysis of Animal Venoms
http://dx.doi.org/10.5772/53773
5
of these new technologies, small peptides from animal venoms with unexplored biological
activities started to be studied systematically, emerging, then, this new area of knowledge
and scientific research called peptidomics. These molecules are potential candidates for new
drugs or compounds with significant therapeutic actions.
2. Chemical composition and strategic importance of venoms
Over 5000 years ago, the Mesopotamians used a cane with a serpent as an emblem of Nin‐
gizzida, the god of fertility, marriage and pests. In Christianity, the serpent has always been
associated with evil because of the biblical allegory of Adam and Eve. There is also a biblical
story in which Moses erected a post with a brazen serpent to release his people from the pla‐
gue of snakes. Throughout the development of Christianity, this symbol was transformed
and the post became a tau.
But not always and not in all cultures, serpents were associated with evil. Many people be‐
lieved in the cure power of serpents, often associated with its venom. Indeed, the medicinal
value of animal venoms has been known since Antiquity. The medicinal use of bee venom,
apitoxin, is reported in ancient Egypt and in Europe and Asia history. Charlemagne and
Ivan the Terrible, for example, would have used apitoxin to treat common diseases. The med‐
ical uses of scorpion and snake venoms are well documented in Chinese pharmacopoeia. In
an Islamic traditional tale, Muhammed is sick and, in the face of no known cure, it allows
the use of snake venom as a last resource.
To Greeks and Romans, the serpent was a symbol of cure because periodically abandons its
old skin and seemingly reborn, in the same way that doctors remove the disease of the body
and rejuvenate the men, and also because the serpent was a symbol of concentrated atten‐
tion, which was required to the curers. However, the association of serpents with cure may
also be related to its venom, represented symbolically by herbs in the Greek-Roman mythol‐
ogy of Aesculapius, the god of medicine and cure. Called to assist Glaucus, who had been
killed by lightning, Aesculapius saw a snake enter the room where he was, and killed it with
his staff. Soon, a second serpent entered the room carrying herbs in its mouth, which depos‐
ited at the mouth of another dead serpent, making it back to life. Watching this scene, Aes‐
culapius decided to put the herbs into the Glaucus mouth, who also raised from dead. Since
then, Aesculapius turned the serpent your pet guardianship. His staff with a coiled serpent
became the symbol of modern medicine in a large number of countries and is present even
in the banner of the World Health Organization (WHO).
However, despite the healing power of animal venoms be known for a long time, the sys‐
tematic investigation of venom components as natural sources for the generation of pharma‐
ceuticals was only performed over the past decades, after a peptide that potencialize
bradykinin action was isolated from the venom of the Brazilian snake Bothrops jararaca [27].
This led to the development, in the 1950s, of the first commercial drug based on angiotensin
I converting enzyme (ACE)-inhibitor (trade name captopril®), for the treatment of arterial
hypertension and heart failure [28]. Prialt® (ziconotide) is another example of synthetic drug
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successfully isolated from an animal venom [11]. This is a synthetic non-opioid peptide,
non-NSAID, non-local anesthetic calcium channel blocker, isolated from the secretions of the
cone snail Conus magus. Prialt® is used for the alleviation of chronic intractable pain and is
administered directly into the spinal cord, due to deep side effects or lack of efficacy when it
is administered by the more common routes such as orally or intravenously.
The evolution of the venom secretion apparatus in animals is indeed an impressive biologi‐
cal achievement at the evolutionary point of view. Since venoms components result of bio‐
chemical and pharmacological refinement over a long period in evolutionary scale, they
have been tuned for optimum activity by the natural evolution. Thus, nature has already
prospected huge combinatorial libraries of potential therapeutic drugs. The biochemical
evolution of proteins from salivary fluids or venom exocrine glands is remarkable, especial‐
ly when one considers the highly specialized functions of these proteins and its high specif‐
icity with respect to the target molecule.
Several classes of organic molecules have been described in venoms, such as alkaloids and
acylpolyamines. However, the main constituents are indeed polypeptides. Venoms of cone
snail and arthropods, such as spiders, scorpions and insects, to a lesser extent, seem to be
mainly peptidic, while snakes produce protein rich venoms. Snake venoms contain a variety
of proteases, which hydrolyze peptide bonds of proteins, nucleases, which hydrolyze phos‐
phodiester bonds of DNA, and neurotoxins, which disable signaling in the nervous system.
The brown spider venom contains a variety of toxins, the most important of which is the tis‐
sue destruction agent sphingomyelinase D, present in the venom of all species of Loxosceles
in different concentrations [29]. Only another spider genus (Sicarius) and several pathogenic
bacteria are known to produce this enzyme.
Some venoms comprise several hundreds of components, which further expands its poten‐
tial as a source of new medicines. Many components of venoms affect the nervous system
and modulate the generation and propagation of action potentials, acting on multiple molec‐
ular sites, which include central and peripheral neurons, axons, synapses and neuromuscu‐
lar junctions [30]. Many of these target receptors play important physiological roles or are
associated with specific diseases. Therefore, the components of animal venoms are impor‐
tant biological tools for studying these receptors, and the discovery of molecules in venoms
with selective activity for these receptors represents a very attractive approach to the search
for new drugs. The venom components may therefore be probed for the development of
new therapies for pain management [31], new anti-arrhythmic [32], anticonvulsant [33] or
anxiolytic drugs [34], new antimicrobial agents [35-37] or pesticides [38, 39], etc. Even a sub‐
stance that causes priapism has been isolated from the venom of a Brazilian spider [40], be‐
coming a potential drug candidate to attend erectile dysfunction.
Another reason to study the composition of animal venoms is trying to seek more effective
prophylaxis for envenomings. Doctors treat victims of venomous sting with serum, which is
produced by injecting into an animal, such as sheep, horse, goat or rabbit, a small amount of
specific venom. The animal’s immune system responds to the target dose, producing anti‐
bodies to active molecules of the venom. These antibodies can then be isolated from the ani‐
mal’s blood and used in envenoming treatment in other animals, including humans.
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However, this treatment can be effectively used only a limited number of times for a partic‐
ular person, since that person will develop antibodies to neutralize the exogenous animal’s
antibodies used to produce the antiserum (antibodies antiantibodies). Even if that person
does not suffer a severe allergic reaction to the antiserum, his own immune system can de‐
stroy the antiserum even before the antiserum destroys the venom toxins. Most people will
never need an antiserum treatment throughout their lives. However, others, who work or
live in risk areas habited by snakes or other venomous animals, such as agricultural areas
for example, need that this treatment is available in public health network.
Some treatments are done not with antiserum, but herbal. Aristolochia rugosa and Aristolochia
trilobata, or angelic, are medicinal plants used in Western India and in Central and South
America against snake and scorpion bites [41]. Aristolochic acid, produced by those plants,
inhibits inflammation induced by immune complexes and non-immunological agents (carra‐
geenan or croton oil). It also inhibits the activity of phospholipases present in snake venoms
(PLA2], forming a 1:1 complex with the enzyme. Phospholipases play an important role in
the reactions cascade that lead to inflammatory response and pain. Therefore, its inhibition
may reduce problems of scorpionism, snakebite and loxoscelism.
3. Proteomic and peptidomic analysis: A new approach to study venoms
Proteins are very large molecules formed by amino acids chains linked together as a poly‐
mer. Although biological systems uses only 20 amino acids to build their proteins, the differ‐
ent possible combinations among them is virtually infinite, resulting in tens of thousands
different proteins, each one with a unique sequence, genetically defined, which determines
its specific form and biological function. Furthermore, each protein may undergo a variety
of post-translational modifications, which diversifies even more its form and function. Pro‐
teins are the main constituents of protoplasm of all cells. As the major components of cells
metabolic pathways, proteins have vital functions in organism, such as: catalyze biochemical
reactions (eg. enzymes), transmit messages (eg. neurotransmitters), regulate cellular repro‐
duction, influence growth and development of various tissues (eg. trophic factors), carry
oxygen in the blood (eg. hemoglobin), defend the body against diseases (eg. antibodies),
among countless other achievements. There is no metabolic reaction in which the participa‐
tion of at least one protein is dispensable.
The term “proteome” is derived from the junction of the word “PROTEin” with the word
“genOME” and refers to the set of proteins expressed starting from a genome, i.e., all the
proteins produced by an organism. Indeed, the word proteome is often be more related to
the set of proteins expressed in a specific organ, or biological fluid, or cell, in a given state
(eg. diseased cell).  The proteome is therefore the complete complement of a genome, in‐
cluding the “makeup” that proteins receives after being synthesized, i.e., the post-transla‐
tional  modifications,  all  of  them  absolutely  relevant  for  that  proteins  perform  their
biological function. The proteome of a cell or fluid varies with time and conditions under
which the organism is subjected. The human body, for example, can contain more than 2
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million different proteins, each one exerting a distinct role. Unlike the genome, which is
relatively static, the proteome is constantly changing in response to tens of thousands of
intra and extracellular environmental signals. The proteome varies with the nature of each
tissue or organ, the cell development stage, the stress conditions to which the organism is
subjected, the organism health state, the effects of drug treatment, etc. As such, the pro‐
teome is often defined as the proteins present in a sample (tissue, organism, cell culture,
biological fluid, etc.) at a given point in time.
The term proteomics consists of comprehensive and systematic study of all proteins present
in a given cell state, which was made possible by the huge development of mass spectrome‐
try techniques over the past two decades. Proteomics and genomics run parallel and are in‐
terdependent. Genomics without proteomics is only an “alphabet soup”, because it can only
make inferences about their products (proteins). Moreover, proteomics requires genomics to
identify the proteins expressed in a particular cell state. Briefly, genomics provides a static
information of the various ways in which a cell may use its proteins, while proteomics gives
a dynamic panorama of molecular diversity, showing not only which proteins are more or
less expressed (or is not even expressed), but also how these proteins were modified and
how these modifications affect its role in the cell theater.
Proteomic technologies can play an important role in new drugs discovery, new diagnos‐
tics and molecular medicine, because it is the connection between genes, proteins and dis‐
eases.  For  example,  the  discovery  of  defective  proteins  that  cause  specific  diseases  can
help develop new drugs that either alter the shape of a defective protein or mimic its ac‐
tion.  Most of  the most popular drugs today either have proteinaceous nature or have a
protein target.  Through proteomics,  one can create  “custom” drugs,  i.e.,  drugs specially
designed for specific individuals. Such drugs are supposed to be more effective and cause
fewer side effects. Another field to which proteomic studies can contribute is the biomark‐
ers  discovery  for  specific  diseases,  whose  overexpression (or  depletion)  would indicate,
quite early, the disease development. For example, serum levels of prostate specific anti‐
gen  (PSA)  is  commonly  used in  the  diagnosis  of  prostate  cancer  in  men,  which  makes
PSA a biomarker for cancer. Unfortunately, however, the diagnosis based on a single pro‐
tein biomarker is not very reliable. Proteomics may help scientists to develop diagnostic
tests that simultaneously analyze the expression of multiple proteins in order to improve
the specificity and sensitivity of these tests.
Over time, new study areas with the suffix “omics” have emerged, such as metabolomics,
lipidomics, carbohydratomics, degradomics etc. The term venomics did not slow to appear,
and today it is defined as the study of all components (protean or not protean) of a venom.
The word peptidomics has also been proposed to set the study of the peptides (instead of
proteins) of a cell type or a biological fluid, such as venom. According to Ivanov and Yatskin
[42]: “structure and biologic function of the entire multitude of peptides circulating in living
organisms, their organs, tissues, cells and fluids comprises the scope of peptidomics”. For
these authors, “these two multitudes of polypeptides (proteins and peptides) play a domi‐
nant role in the functioning of any cellular system, tissue or organ. They are intimately con‐
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nected with each other and exist in equilibrium as an essential part of homeostasis (i.e., the
normal state of any living organism and the basis of life itself)”.
Peptidomic analysis has been proposed by several authors [43-55] as a way to access infor‐
mation relevant to clinical diagnosis and/or to monitor the patient biochemical profile dur‐
ing the therapy. The growing interest in peptidomic analysis led some scientists to develop
new analytical technologies to improve peptidomic analysis, such as: use of capillary elec‐
trophoresis to separate the peptides [46]; use of size exclusion chromatography as a pre-frac‐
tionation step [53, 56]; new technologies and methods for sample pretreatment [57], such as
methods for isolation rare amino acid-containing peptides, terminal peptides, PTM peptides
and endogenous peptides, automated sample pretreatment technologies (automated sample
injection and on-line digestion) [58]; development of a new target plate for MALDI-MS for
one step electric transfer of analytes from a 1-dimensional electrophoresis gel directly to the
target plate [59, 60]; etc. In recent years, in the face of the remarkable development on nano‐
technology, many researchers have produced different kind of nanoparticles, such as meso‐
porous silica nanoparticles [50, 51, 61, 62] and carbon nanotubes [52, 63], for selective
peptide extraction (and, hence, its enrichment) from biological fluids for therapeutic purpos‐
es (clinical diagnosis and/or novel biomarker discovery).
In the case of animal venoms, however, peptidomics is a highly interesting area for differ‐
ent reasons, since most of the biologically active components of pharmacological interest
are  of  peptidic  nature  [64].  For  example,  Biass  and  co-workers  [12]  studied  the  venom
peptidomic profile  of  the cone snail-hunting fish,  Conus consors,  through approaches in‐
volving  different  sample  preparation  protocols  and analysis  by  mass  spectrometry.  The
cone snail was quoted in the television series Animal Planet: The Most Extreme,  because it
can quickly shoot a harpoon filled with deadly toxins. The conidia (Conidae) constitute a
family of several shells divided into subfamilies.  It  is  estimated that this genus produce
more than 70,000 different pharmacologically active components, most of peptidic nature,
whereas interspecies variations. It is a rich library of neuropharmacology and combinato‐
rial  chemistry.  Precisely for this  reason,  the 6th  Framework Programme of  the European
Union funded with € 10.7 million the international project CONCO involving 20 partners
and 13 countries  [65],  whose objective  is  to  explore  new molecules  therapeutically  rele‐
vant produced by venomous marine cone snails.
4. The tools to peptidomic analysis
Mass spectrometry is an analytical tool that has evolved dramatically over the past 20 years
in terms of sensitivity, resolving power and versatility, and is currently one of the main tools
for studying the molecular components of biological systems, including venoms. The devel‐
opment of techniques such as electrospray ionization (ESI) and matrix-assisted laser desorp‐
tion ionization (MALDI) was essential for allowing polypeptides be analyzed by mass
spectrometry. Hyphenation of separation techniques such as high performance liquid chro‐
matography (HPLC) with mass spectrometry was also decisive for this progress. As a conse‐
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quence, the highly combinatorial nature of venom components and their underlying
pharmacologic complexity have been progressively revealed by mass spectrometry. Cur‐
rently, major challenges remain on samples complexity, lack of biological material and data‐
bases absence to peptide and protein identification based on sequence information.
Peptidomic analysis of a sample will consist of essentially four steps: (I) peptides extraction
from the sample; (II) separation of these peptides — including their prior separation from
other polypetidic components of the sample, i.e., proteins, defined as the protean compo‐
nents with molecular weight above 10 kDa —; (III) peptides detection — which is commonly
performed by mass spectrometry —, (IV) and finally identification of the peptides — which
usually involves fragmentation of those peptides in a tandem mass spectrometer (MS/MS).
With respect to peptide sequencing for identification purposes, the technique traditionally
used is Edman degradation-based sequencing [66, 67]. But nowadays this kind of sequenc‐
ing is increasingly being replaced by sequencing techniques based on mass spectrometry
[68, 69]. This is due to the fact that mass spectrometry is much more rapid and sensitive than
Edman sequencing and prenscinde of prior separation of the peptides, which means that
peptides can be sucessfully analyzed and sequenced by mass spectrometry from a complex
peptide matrix, which is impossible by Edman sequencing. This is only possible because the
peptide of interest is selected (i.e., separated from others) in the first mass spectrometer.
Then, this parent ion is fragmented in a collision chamber and the daughter ions are ana‐
lyzed in a second mass spectrometer (MS/MS). Figure 3 gives an example of peptide de novo
sequencing by tandem mass spectrometry. For more details about this kind of polypeptide
sequencing, see reference [69].
In proteomics, the most widely used technique to separate protean components of a sample
is the two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). In peptidomics,
however, techniques based on liquid chromatography coupled to mass spectrometry (LC-
MS) appear to be more popular, since peptides are not well resolved by electrophoresis [70].
Despite this, capillary electrophoresis has also been used successfully in peptidomic analy‐
sis, mainly to analyze biological fluids for clinical applications, such as disease diagnosis
and response to therapy [46].
As an example, Valente and co-workers [71] ran a two-dimensional gel from the venom of
Bothrops insularis, an endemic snake specie in Queimada Grande Island, Brazil. The result is
shown in Figure 1. This is an example of venomics, i.e., the study of all protean components
of a venom. Using the proteomic approach, the authors detected 494 spots in the gel using
an image analysis software, from which 69 proteins were identified by current identification
techniques, using mass spectrometry and heavy bioinformatics to interpret the mass spectra
and also to make a comparative search of protein sequences deposited in databases. The
identified proteins include metalloproteinases, serine proteinases, phospholipases A2, lec‐
tins, growth factors, L-amino acid oxidases, the developmental protein G10, a disintegrin, a
nuclear protein of the BUD31 family, and putative novel bradykinin-potentiating peptides.
In the same study, the authors also performed a peptidomic analysis of the venom, by direct
analysis of the crude venom by MALDI-TOF-TOF and LC-ESI-Q-TOF. Many new peptides
were partially or completely sequenced by both MALDI-MS/MS and LC-ESI-MS/MS. Using
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the proteomic approach associated with peptidomic analysis, the authors could speculate
about the existence of posttranslational modifications and a proteolytic processing of precur‐
sor molecules which could lead to diverse multifunctional proteins.
Figure 1. Proteomic profile of Bothrops insularis venom: 2D-PAGE reference map (copyed from reference [71]).
Liao and co-workers [72] also applied proteomic and peptidomic approaches together to an‐
alyze the venom of Chilobrachys jingzhao (a type of tarantula; one of the most venomous spi‐
ders in southern China). They developed a protocol which consists in run a gel filtration of
the crude venom and then divide the fractions in two parts. The fraction containing protean
components with molecular mass above 10 kDa they underwent proteomic analysis, which
consisted of 2-DE, in gel trypsin digestion, MALDI-TOF-TOF and ESI-Q-TOF analysis of the
spots, protein identification by PMF, de novo sequencing of the peptides, and protein identi‐
fication by MS BLAST sequence similarity search. The fraction containing protein compo‐
nents with molecular weight below 10 kDa was used for peptidomic analysis, consisting in
separation of the peptides by ion-exchange HPLC followed by reverse phase HPLC, MAL‐
DI-TOF analysis of the chromatographic fractions, Edman peptide sequencing, and peptide
identification by MS BLAST. The authors reported that peptides were the predominant com‐
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ponents [69%) of the dry crude venom, while proteins accounted only for 6%. Nonprotean
components (low MW inorganic and organic molecules, such as polyamines, salts, free
acids, glucose, etc.) complete the remaining 25% of the crude venom.
Another good example of peptidomic analysis was presented by Rates and co-workers [73],
who studied the Tityus serrulatus (a specie of scorpion whose venom has been most exten‐
sively studied) venom peptide diversity. In this work, the authors fracionated the venom by
gel filtration followed by reverse phase chromatography of each fraction obtained in the first
separation. The results are shown in Figure 2. Then, the chromatographic fractions were an‐
alyzed by MALDI-TOF-TOF. The peptides were sequenced using de novo methodology (Fig‐
ure 3) and the sequences obtained were compared with protein databases in sequence
similarity searches. The authors also reported the finding of novel peptides without se‐
quence similarities to other known molecules.
 
(a) (b) 
Figure 2. Tityus serrulatus venom fractionation through gel filtration (A) and re-chromatography of each fraction by
reverse phase chromatography (B) (copyed from reference [73]).
One of the biggest difficulties currently encountered by researchers working with peptido‐
mic analysis  of  animal venoms is  that  organisms with unsequenced genomes,  including
venomous animals, still represent the overwhelming majority of species in the biosphere.
Fortunately, Andrej Shevchenko, from Max Planck Institute of Molecular Cell Biology and
Genetics,  at  Dresden,  Germany,  paved  the  way  for  homology-driven  proteomic  ap‐
proaches to explore proteomes of organisms with unsequenced genomes [74-76]. Through
this new methodology, the search against sequences databases is made not by the exact
sequence, but by sequence similarity to other protein sequences deposited in the database.
This new approach does not fully solve the problem, but allows peptides to be positively
identified in peptidomic experiments through cross-species identification. Wang and col‐
leagues  [77]  developed an alternative  strategy to  circumvent  the  problem of  absence  of
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systematic online database information, and used this technique to analyze the peptidome
of amphibian skin secretions. Although amphibian skin secretion is not exactly a venom,
it is still a biological model also very promising for the search of new pharmacologically
active substances.  First,  the authors deduced all  of  putative bioactive peptide sequences
by shotgun cloning the cDNAs encoding peptide precursors. Then, they separated the en‐
tire peptidome by UPLC/MS/MS, and confirmed those sequences deduced before by de no‐
vo MS/MS sequencing.
Figure 3. MS/MS spectra interpretation (de novo sequencing) for peptide NH2-FPFNSD(K/Q)GFH(K/Q)-CO2H (copyed
from reference [73]). The K/Q denotes a doubt about the possibility of being lysine or glutamine, as these two amino
acids are isobaric. However, as trypsin cleaves on C-terminal sides of arginines and lysines, it is likely that the middle
amino acid is glutamine and the last one is lysine.
5. Concluding remarks
Animal venoms are true “cocktails” of substances normally harmful, but that can be ex‐
plored with intelligence for medical use. Many authors even use the word “cornucopia” to
define a venom. The cornucopia — junction of the Latin “cornu” (horn) with “copiae”
(strength) -, also called “horn of plenty”, is a symbol of nourishment and abundance in clas‐
sical mythology, usually represented by a large horn-shaped container overflowing with
products such as flowers, dried fruit, other foodstuffs, and other types of wealthiness.
Nowadays it is particularly associated with the Thanksgiving holiday. In toxinology, cornu‐
copia represents the chemical wealth of animal venoms, where one can find thousands of
such substances with interesting biological effects that can be explored as candidates for fu‐
ture pharmaceutical products.
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Much (perhaps the largest) of this pool of substances is of peptidic nature, i.e., polypeptides
with molecular weight below 10 kDa. These are biologically active peptides with diverse
functions, ranging from heart hypotensors to erectile dysfunction controllers. Thus, the pep‐
tidomic analysis of animal venoms is an emerging and promising area of science, and can be
considered a frontier area as it includes researchers from toxinology, proteomics, pharma‐
cology, therapeutics, drug discovery, peptide chemistry, analytical chemistry, etc.
In this chapter we tried to show the importance of animal venoms for molecular toxinology
and its potential use for biomedical applications. We also sought to demonstrate the recent
advent and rapid growth of peptidomic analysis as the main tool to explore the molecular
features of these venoms, not only to produce more efficient antisera against venomous bites
but also and mainly to characterize the components of peptide nature in search for new
products of pharmacological interest. Although this new science is still in its early stages of
development, it is already very mature. This is a science field that has enough potential to
grow and provide creative solutions to problems that affect human health. Hopefully more
and more researchers become interested on this topic. Medicine has much to gain from it.
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